Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mHealth-Supported Exercise Rehabilitation to Reverse Frailty After Autologous Transplantation in Multiple Myeloma: Randomized Controlled Trial.

JMIR mHealth and uHealth·2026
Same author

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

American journal of hematology·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026
Same author

Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population.

International journal of cancer·2026
Same author

Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.

Journal of the American Heart Association·2025
Same author

Orbital Compartment Syndrome as a Complication of Blepharoplasty: A Case Report.

Clinical practice and cases in emergency medicine·2025

Related Experiment Video

Updated: Jul 12, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Talquetamab in multiple myeloma.

Lawrence Liu1, Amrita Krishnan2

  • 1Judy and Bernard Briskin Center for Multiple Myeloma Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA. laliu@coh.org.

Haematologica
|October 19, 2023
PubMed
Summary

Talquetamab, a new bispecific antibody, shows promising efficacy and durability for relapsed or refractory multiple myeloma. This therapy offers an alternative with a different side effect profile compared to existing treatments.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K

Related Experiment Videos

Last Updated: Jul 12, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Multiple myeloma remains a significant challenge, especially in relapsed or refractory cases.
  • Existing therapies have limitations, necessitating novel treatment approaches.
  • Bispecific antibodies represent a promising advancement in multiple myeloma treatment.

Purpose of the Study:

  • To report initial results from a phase I trial of talquetamab.
  • To evaluate the efficacy and safety of talquetamab in patients with relapsed or refractory multiple myeloma.
  • To compare talquetamab with existing bispecific antibody therapies.

Main Methods:

  • Phase I clinical trial.
  • Talquetamab, a bispecific antibody targeting GPRC5D and CD3.
  • Treatment setting: fourth line or later for relapsed or refractory multiple myeloma.

Main Results:

  • Talquetamab demonstrated comparable efficacy and response durability to teclistamab.
  • Fewer infections were observed with talquetamab compared to teclistamab.
  • Unique class-specific side effects were noted, including skin, oral, and nail toxicities.

Conclusions:

  • Talquetamab is a highly efficacious and well-tolerated therapy for heavily pretreated multiple myeloma.
  • It offers a valuable addition to the therapeutic options for relapsed or refractory multiple myeloma.
  • The distinct side effect profile warrants careful monitoring and management.